[2-(3-methoxyphenyl)-5-methylphenyl]-[(2S)-2-methyl-2-(1,5,6-trimethylbenzimidazol-2-yl)pyrrolidin-1-yl]methanone
C30H33N3O2 — CID 118127508
Data last refreshed: (MolForge compound catalog, from PubChem)
About [2-(3-methoxyphenyl)-5-methylphenyl]-[(2S)-2-methyl-2-(1,5,6-trimethylbenzimidazol-2-yl)pyrrolidin-1-yl]methanone
[2-(3-methoxyphenyl)-5-methylphenyl]-[(2S)-2-methyl-2-(1,5,6-trimethylbenzimidazol-2-yl)pyrrolidin-1-yl]methanone (PubChem CID 118127508) has the molecular formula C30H33N3O2 and a molecular weight of 467.61 g/mol. Its IUPAC name is [2-(3-methoxyphenyl)-5-methylphenyl]-[(2S)-2-methyl-2-(1,5,6-trimethylbenzimidazol-2-yl)pyrrolidin-1-yl]methanone.
Molecular Properties
| Compound Name | [2-(3-methoxyphenyl)-5-methylphenyl]-[(2S)-2-methyl-2-(1,5,6-trimethylbenzimidazol-2-yl)pyrrolidin-1-yl]methanone |
|---|---|
| PubChem CID | 118127508 |
| Molecular Formula | C30H33N3O2 |
| Molecular Weight | 467.61 g/mol |
| Exact Mass | 467.26 |
| IUPAC Name | [2-(3-methoxyphenyl)-5-methylphenyl]-[(2S)-2-methyl-2-(1,5,6-trimethylbenzimidazol-2-yl)pyrrolidin-1-yl]methanone |
| SMILES | COc1cccc(-c2ccc(C)cc2C(=O)N2CCC[C@@]2(C)c2nc3cc(C)c(C)cc3n2C)c1 |
| InChI | InChI=1S/C30H33N3O2/c1-19-11-12-24(22-9-7-10-23(18-22)35-6)25(15-19)28(34)33-14-8-13-30(33,4)29-31-26-16-20(2)21(3)17-27(26)32(29)5/h7,9-12,15-18H,8,13-14H2,1-6H3/t30-/m0/s1 |
| InChIKey | IKJOUBXNNPJOFV-PMERELPUSA-N |
| XLogP | 6.33 |
| TPSA | 47.36 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 35 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 467.61 |
| LogP ≤ 5 | 6.33 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 118127508 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.